|

Temozolomide+Irinotecan+Vincristine Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

  • Yizhuo Zhang1
  • Sun Yat-sen University1

Indications

  • Cancer2
  • Rhabdomyosarcoma, Child1
  • Soft Tissue Sarcoma1

Other2 trials

Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.
Phase 2
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.